

# **Global Hyperphosphatemia Therapeutics Market Size Study & Forecast, by Drug Class (Sevelamer, Calcium-based Phosphate Binders, Lanthanum Carbonate, Iron-based Phosphate Binders, Non-Phosphate Binders, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Analysis, 2023-2030**

<https://marketpublishers.com/r/GC1AF5F99B70EN.html>

Date: April 2024

Pages: 200

Price: US\$ 4,950.00 (Single User License)

ID: GC1AF5F99B70EN

## **Abstracts**

Global Hyperphosphatemia Therapeutics Market is valued at approximately USD 1.23 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.2% over the forecast period 2023-2030. Hyperphosphatemia treatment aims to manage elevated levels of phosphate in the blood, a condition often associated with chronic kidney disease (CKD) and other renal disorders. Treatment modalities typically include dietary modifications to limit phosphate intake, phosphate binders to reduce absorption in the gastrointestinal tract, and medications to enhance phosphate excretion through the kidneys. Phosphate binders, such as calcium-based or non-calcium-based agents, help lower phosphate levels by binding to dietary phosphate in the gut and preventing its absorption into the bloodstream. Additionally, medications like tenapanor may be used to reduce phosphate absorption in the intestines. Dialysis is often employed in advanced CKD stages to remove excess phosphate from the blood. The choice of treatment depends on the severity of hyperphosphatemia, underlying kidney function, and individual patient factors. Phosphate monitoring and management of phosphate levels are crucial to prevent complications such as cardiovascular disease, bone disorders, and soft tissue calcifications. The Hyperphosphatemia Therapeutics Market is expanding because of factors such as the growing public awareness and improved diagnostic capabilities, growth of kidney dialysis, coupled with the increasing aging populations and advancements in drug therapeutics.

In addition, the rising prevalence of chronic kidney disease (CKD) is driving the need for efficient Hyperphosphatemia treatments, which is acting as a catalyzing factor for market growth across the globe. For instance, in 2023, the U.S. Centers for Disease Control and Prevention (CDC) reported that 35.5 million individuals, comprising 14% of the U.S. populace, were afflicted by CKD. Hyperphosphatemia is prevalent among CKD and dialysis patients. Thus, the rising burden of these conditions correlate with increased Hyperphosphatemia occurrence. Thus, these aforementioned factors are propelling the growth of the Hyperphosphatemia Therapeutics Market during the estimated period. Moreover, the rising development of innovative hyperphosphatemia treatment options, as well as the increasingly implementing reimbursement policies present various lucrative opportunities over the forecast years. However, the complications from use of hyperphosphatemia therapeutics and poor medical adherence are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Hyperphosphatemia Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising population of CKD patients undergoing dialysis. As per the data released by the National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) in May 2023, approximately 808,000 individuals in the U.S. were living with End-Stage Renal Disease (ESRD), with 69% of them undergoing dialysis. This demographic trend is expected to markedly drive the demand for hyperphosphatemia therapeutics throughout the forecast period. Whereas Asia Pacific is expected to grow at the highest CAGR over the forecast years. The prevalent usage of calcium-based phosphate binders compared to developed nations are significantly propelling the market demand across the region. Also, evolving prescription trends in these regions and a notably larger population undergoing dialysis contribute significantly to the heightened demand for hyperphosphatemia treatment across Asia Pacific in the forecast period.

Major market players included in this report are:

Sanofi SE

Takeda Pharmaceutical Company Limited

Lupin Limited

Astellas Pharma Inc.

Akebia Therapeutics, Inc.

CSL Limited

Ardelyx, Inc.

Unicycive, Inc.

Amag Pharmaceuticals Inc

Akebia Therapeutics Inc.

Recent Developments in the Market:

In August 2023, Astellas Pharma Inc. and DivcoWest, a DivCore Capital Company, collaborated with the aim of launching Astellas' new life science center on Morgan Avenue in Cambridge.

In July 2023, Ardelyx obtained approval for the use of Tenapanor as a hyperphosphatemia treatment in China. This regulatory clearance has facilitated the company's global market expansion by strengthening its presence in the international healthcare landscape.

Global Hyperphosphatemia Therapeutics Market Report Scope:

Historical Data – 2020 - 2021

Base Year for Estimation – 2022

Forecast period - 2023-2030

Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered - Drug Class, Distribution Channel, Region

Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope\*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

Sevelamer

Calcium-based Phosphate Binders

Lanthanum Carbonate

Iron-based Phosphate Binders

Non-Phosphate Binders

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

## Contents

### CHAPTER 1. EXECUTIVE SUMMARY

- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  - 1.2.1. Hyperphosphatemia Therapeutics Market, by Region, 2020-2030 (USD Billion)
  - 1.2.2. Hyperphosphatemia Therapeutics Market, by Drug Class, 2020-2030 (USD Billion)
  - 1.2.3. Hyperphosphatemia Therapeutics Market, by Distribution Channel, 2020-2030 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption

### CHAPTER 2. GLOBAL HYPERPHOSPHATEMIA THERAPEUTICS MARKET DEFINITION AND SCOPE

- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
  - 2.2.1. Industry Evolution
  - 2.2.2. Scope of the Study
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates

### CHAPTER 3. GLOBAL HYPERPHOSPHATEMIA THERAPEUTICS MARKET DYNAMICS

- 3.1. Hyperphosphatemia Therapeutics Market Impact Analysis (2020-2030)
  - 3.1.1. Market Drivers
    - 3.1.1.1. Increasing public awareness and improved diagnostic capabilities
    - 3.1.1.2. Rising prevalence of chronic kidney disease (CKD)
  - 3.1.2. Market Challenges
    - 3.1.2.1. Complications from use of hyperphosphatemia therapeutics
    - 3.1.2.2. Poor medical adherence
  - 3.1.3. Market Opportunities
    - 3.1.3.1. Rising development of innovative hyperphosphatemia treatment options
    - 3.1.3.2. Increasingly implementing reimbursement policies

## **CHAPTER 4. GLOBAL HYPERPHOSPHATEMIA THERAPEUTICS MARKET INDUSTRY ANALYSIS**

- 4.1. Porter's 5 Force Model
  - 4.1.1. Bargaining Power of Suppliers
  - 4.1.2. Bargaining Power of Buyers
  - 4.1.3. Threat of New Entrants
  - 4.1.4. Threat of Substitutes
  - 4.1.5. Competitive Rivalry
- 4.2. Porter's 5 Force Impact Analysis
- 4.3. PEST Analysis
  - 4.3.1. Political
  - 4.3.2. Economical
  - 4.3.3. Social
  - 4.3.4. Technological
  - 4.3.5. Environmental
  - 4.3.6. Legal
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. COVID-19 Impact Analysis
- 4.7. Disruptive Trends
- 4.8. Industry Expert Perspective
- 4.9. Analyst Recommendation & Conclusion

## **CHAPTER 5. GLOBAL HYPERPHOSPHATEMIA THERAPEUTICS MARKET, BY DRUG CLASS**

- 5.1. Market Snapshot
- 5.2. Global Hyperphosphatemia Therapeutics Market by Drug Class, Performance - Potential Analysis
- 5.3. Global Hyperphosphatemia Therapeutics Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
- 5.4. Hyperphosphatemia Therapeutics Market, Sub Segment Analysis
  - 5.4.1. Sevelamer
  - 5.4.2. Calcium-based Phosphate Binders
  - 5.4.3. Lanthanum Carbonate
  - 5.4.4. Iron-based Phosphate Binders
  - 5.4.5. Others
  - 5.4.6. Non-Phosphate Binders



## **CHAPTER 6. GLOBAL HYPERPHOSPHATEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL**

- 6.1. Market Snapshot
- 6.2. Global Hyperphosphatemia Therapeutics Market by Distribution Channel, Performance - Potential Analysis
- 6.3. Global Hyperphosphatemia Therapeutics Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
- 6.4. Hyperphosphatemia Therapeutics Market, Sub Segment Analysis
  - 6.4.1. Hospital Pharmacies
  - 6.4.2. Retail Pharmacies
  - 6.4.3. Online Pharmacies

## **CHAPTER 7. GLOBAL HYPERPHOSPHATEMIA THERAPEUTICS MARKET, REGIONAL ANALYSIS**

- 7.1. Top Leading Countries
- 7.2. Top Emerging Countries
- 7.3. Hyperphosphatemia Therapeutics Market, Regional Market Snapshot
- 7.4. North America Hyperphosphatemia Therapeutics Market
  - 7.4.1. U.S. Hyperphosphatemia Therapeutics Market
    - 7.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
    - 7.4.1.2. Distribution Channel breakdown estimates & forecasts, 2020-2030
  - 7.4.2. Canada Hyperphosphatemia Therapeutics Market
- 7.5. Europe Hyperphosphatemia Therapeutics Market Snapshot
  - 7.5.1. U.K. Hyperphosphatemia Therapeutics Market
  - 7.5.2. Germany Hyperphosphatemia Therapeutics Market
  - 7.5.3. France Hyperphosphatemia Therapeutics Market
  - 7.5.4. Spain Hyperphosphatemia Therapeutics Market
  - 7.5.5. Italy Hyperphosphatemia Therapeutics Market
  - 7.5.6. Rest of Europe Hyperphosphatemia Therapeutics Market
- 7.6. Asia-Pacific Hyperphosphatemia Therapeutics Market Snapshot
  - 7.6.1. China Hyperphosphatemia Therapeutics Market
  - 7.6.2. India Hyperphosphatemia Therapeutics Market
  - 7.6.3. Japan Hyperphosphatemia Therapeutics Market
  - 7.6.4. Australia Hyperphosphatemia Therapeutics Market
  - 7.6.5. South Korea Hyperphosphatemia Therapeutics Market
  - 7.6.6. Rest of Asia Pacific Hyperphosphatemia Therapeutics Market

- 7.7. Latin America Hyperphosphatemia Therapeutics Market Snapshot
  - 7.7.1. Brazil Hyperphosphatemia Therapeutics Market
  - 7.7.2. Mexico Hyperphosphatemia Therapeutics Market
- 7.8. Middle East & Africa Hyperphosphatemia Therapeutics Market
  - 7.8.1. Saudi Arabia Hyperphosphatemia Therapeutics Market
  - 7.8.2. South Africa Hyperphosphatemia Therapeutics Market
  - 7.8.3. Rest of Middle East & Africa Hyperphosphatemia Therapeutics Market

## **CHAPTER 8. COMPETITIVE INTELLIGENCE**

- 8.1. Key Company SWOT Analysis
  - 8.1.1. Company
  - 8.1.2. Company
  - 8.1.3. Company
- 8.2. Top Market Strategies
- 8.3. Company Profiles
  - 8.3.1. Sanofi SE
    - 8.3.1.1. Key Information
    - 8.3.1.2. Overview
    - 8.3.1.3. Financial (Subject to Data Availability)
    - 8.3.1.4. Product Summary
    - 8.3.1.5. Recent Developments
  - 8.3.2. Takeda Pharmaceutical Company Limited
  - 8.3.3. Lupin Limited
  - 8.3.4. Astellas Pharma Inc.
  - 8.3.5. Akebia Therapeutics, Inc.
  - 8.3.6. CSL Limited
  - 8.3.7. Ardelyx Inc.
  - 8.3.8. Unicycive Inc.
  - 8.3.9. Amag Pharmaceuticals Inc
  - 8.3.10. Akebia Therapeutics Inc.

## **CHAPTER 9. RESEARCH PROCESS**

- 9.1. Research Process
  - 9.1.1. Data Mining
  - 9.1.2. Analysis
  - 9.1.3. Market Estimation
  - 9.1.4. Validation

- 9.1.5. Publishing
- 9.2. Research Attributes
- 9.3. Research Assumption

## List Of Tables

### LIST OF TABLES

TABLE 1. Global Hyperphosphatemia Therapeutics Market, report scope

TABLE 2. Global Hyperphosphatemia Therapeutics Market estimates & forecasts by Region 2020-2030 (USD Billion)

TABLE 3. Global Hyperphosphatemia Therapeutics Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)

TABLE 4. Global Hyperphosphatemia Therapeutics Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)

TABLE 5. Global Hyperphosphatemia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)

TABLE 6. Global Hyperphosphatemia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)

TABLE 7. Global Hyperphosphatemia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)

TABLE 8. Global Hyperphosphatemia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)

TABLE 9. Global Hyperphosphatemia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)

TABLE 10. Global Hyperphosphatemia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)

TABLE 11. Global Hyperphosphatemia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)

TABLE 12. Global Hyperphosphatemia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)

TABLE 13. Global Hyperphosphatemia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)

TABLE 14. Global Hyperphosphatemia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)

TABLE 15. U.S. Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 16. U.S. Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 17. U.S. Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 18. Canada Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 19. Canada Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 20. Canada Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 21. UK Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 22. UK Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 23. UK Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 24. Germany Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 25. Germany Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 26. Germany Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 27. France Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 28. France Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 29. France Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 30. Italy Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 31. Italy Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 32. Italy Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 33. Spain Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 34. Spain Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 35. Spain Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 36. RoE Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 37. RoE Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 38. RoE Hyperphosphatemia Therapeutics Market estimates & forecasts by

segment 2020-2030 (USD Billion)

TABLE 39. China Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 40. China Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 41. China Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 42. India Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 43. India Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 44. India Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 45. Japan Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 46. Japan Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 47. Japan Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 48. South Korea Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 49. South Korea Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 50. South Korea Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 51. Australia Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 52. Australia Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 53. Australia Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 54. RoAPAC Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 55. RoAPAC Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 56. RoAPAC Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 57. Brazil Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 58. Brazil Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 59. Brazil Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 60. Mexico Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 61. Mexico Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 62. Mexico Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 63. RoLA Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 64. RoLA Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 65. RoLA Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 66. Saudi Arabia Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 67. South Africa Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 68. RoMEA Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 69. List of secondary sources, used in the study of global Hyperphosphatemia Therapeutics Market

TABLE 70. List of primary sources, used in the study of global Hyperphosphatemia Therapeutics Market

TABLE 71. Years considered for the study

TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

## List Of Figures

### LIST OF FIGURES

- FIG 1. Global Hyperphosphatemia Therapeutics Market, research methodology
  - FIG 2. Global Hyperphosphatemia Therapeutics Market, Market estimation techniques
  - FIG 3. Global Market size estimates & forecast methods
  - FIG 4. Global Hyperphosphatemia Therapeutics Market, key trends 2022
  - FIG 5. Global Hyperphosphatemia Therapeutics Market, growth prospects 2023-2030
  - FIG 6. Global Hyperphosphatemia Therapeutics Market, porters 5 force model
  - FIG 7. Global Hyperphosphatemia Therapeutics Market, pest analysis
  - FIG 8. Global Hyperphosphatemia Therapeutics Market, value chain analysis
  - FIG 9. Global Hyperphosphatemia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
  - FIG 10. Global Hyperphosphatemia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
  - FIG 11. Global Hyperphosphatemia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
  - FIG 12. Global Hyperphosphatemia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
  - FIG 13. Global Hyperphosphatemia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
  - FIG 14. Global Hyperphosphatemia Therapeutics Market, regional snapshot 2020 & 2030
  - FIG 15. North America Hyperphosphatemia Therapeutics Market 2020 & 2030 (USD Billion)
  - FIG 16. Europe Hyperphosphatemia Therapeutics Market 2020 & 2030 (USD Billion)
  - FIG 17. Asia pacific Hyperphosphatemia Therapeutics Market 2020 & 2030 (USD Billion)
  - FIG 18. Latin America Hyperphosphatemia Therapeutics Market 2020 & 2030 (USD Billion)
  - FIG 19. Middle East & Africa Hyperphosphatemia Therapeutics Market 2020 & 2030 (USD Billion)
- List of tables and figures and dummy in nature, final lists may vary in the final deliverable



## I would like to order

Product name: Global Hyperphosphatemia Therapeutics Market Size Study & Forecast, by Drug Class (Sevelamer, Calcium-based Phosphate Binders, Lanthanum Carbonate, Iron-based Phosphate Binders, Non-Phosphate Binders, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Analysis, 2023-2030

Product link: <https://marketpublishers.com/r/GC1AF5F99B70EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC1AF5F99B70EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970